MX2023006830A - Inmunocitoquina para activar el receptor il-10ra humano y su uso. - Google Patents

Inmunocitoquina para activar el receptor il-10ra humano y su uso.

Info

Publication number
MX2023006830A
MX2023006830A MX2023006830A MX2023006830A MX2023006830A MX 2023006830 A MX2023006830 A MX 2023006830A MX 2023006830 A MX2023006830 A MX 2023006830A MX 2023006830 A MX2023006830 A MX 2023006830A MX 2023006830 A MX2023006830 A MX 2023006830A
Authority
MX
Mexico
Prior art keywords
immunocytokine
receptor
methods
pharmaceutical compositions
treating
Prior art date
Application number
MX2023006830A
Other languages
English (en)
Inventor
Stanislav Rudolfovich Evdokimov
Valery Vladimirovich Solovyev
Dmitry Valentinovich Morozov
Sergei Andreevich Ageev
Pavel Andreevich Iakovlev
Iana Andreevna Smirnova
Vladimir Sergeevich Tsympilov
Aleksey Vladimirovich Kononov
Iuliia Viktorovna Evdokimovskaia
Elena Sergeevna Kolosova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020140807A external-priority patent/RU2810750C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MX2023006830A publication Critical patent/MX2023006830A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a una inmunocitoquina para activar el receptor IL-10Ra humano. La invención se refiere además a ácidos nucleicos que codifican dicha inmunocitoquina, vectores de expresión, células huésped y métodos para producirlos, métodos para producir la inmunocitoquina, composiciones farmacéuticas que comprenden la inmunocitoquina mencionada, composiciones farmacéuticas que comprenden la inmunocitoquina mencionada y otros compuestos terapéuticamente activos, métodos para tratar una enfermedad oncológica y los usos de la inmunocitoquina o de las composiciones farmacéuticas de la misma para tratar una enfermedad oncológica.
MX2023006830A 2020-12-10 2021-12-10 Inmunocitoquina para activar el receptor il-10ra humano y su uso. MX2023006830A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020140807A RU2810750C2 (ru) 2020-12-10 Иммуноцитокин для активации IL-10Rα рецептора человека и его применение
PCT/RU2021/050432 WO2022124950A1 (en) 2020-12-10 2021-12-10 Immunocytokine for activating human il-10ra receptor and use thereof

Publications (1)

Publication Number Publication Date
MX2023006830A true MX2023006830A (es) 2023-07-06

Family

ID=81973601

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006830A MX2023006830A (es) 2020-12-10 2021-12-10 Inmunocitoquina para activar el receptor il-10ra humano y su uso.

Country Status (18)

Country Link
US (1) US20240034764A1 (es)
EP (1) EP4259644A1 (es)
JP (1) JP2023553934A (es)
KR (1) KR20230118919A (es)
CN (1) CN117120461A (es)
AR (1) AR124310A1 (es)
AU (1) AU2021398529A1 (es)
CA (1) CA3201656A1 (es)
CL (1) CL2023001677A1 (es)
CO (1) CO2023007563A2 (es)
CR (1) CR20230243A (es)
EC (1) ECSP23043458A (es)
IL (1) IL303501A (es)
MA (1) MA61003A1 (es)
MX (1) MX2023006830A (es)
TW (1) TW202237631A (es)
UY (1) UY39562A (es)
WO (1) WO2022124950A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015001675A (es) * 2012-08-08 2015-04-10 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas.
CN106061997A (zh) * 2014-02-06 2016-10-26 豪夫迈·罗氏有限公司 白介素‑10免疫缀合物

Also Published As

Publication number Publication date
ECSP23043458A (es) 2023-07-31
US20240034764A1 (en) 2024-02-01
IL303501A (en) 2023-08-01
CO2023007563A2 (es) 2023-07-21
WO2022124950A1 (en) 2022-06-16
CN117120461A (zh) 2023-11-24
CR20230243A (es) 2023-07-13
UY39562A (es) 2022-05-31
EP4259644A1 (en) 2023-10-18
KR20230118919A (ko) 2023-08-14
MA61003A1 (fr) 2023-10-31
TW202237631A (zh) 2022-10-01
JP2023553934A (ja) 2023-12-26
CA3201656A1 (en) 2022-06-16
AU2021398529A1 (en) 2023-06-29
CL2023001677A1 (es) 2024-01-19
AR124310A1 (es) 2023-03-15

Similar Documents

Publication Publication Date Title
AU2017312113B2 (en) Nucleic acid products and methods of administration thereof
US11504404B2 (en) Skin probiotic formulation
BR112016029581B1 (pt) Propionibacterium acnes geneticamente modificada, composição e seus usos
Li et al. Intravenous administration of atorvastatin-pretreated mesenchymal stem cells improves cardiac performance after acute myocardial infarction: role of CXCR4
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
CN109477102A (zh) 核酸产品及其施用方法
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
MY171356A (en) Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
EP4253406A3 (en) Novel polypeptides and medical uses thereof
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
JP2017511133A5 (es)
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도
Shi et al. Expression, purification, and characterization of scar tissue neovasculature endothelial cell-targeted rhIL10 in Escherichia coli
MX2023006830A (es) Inmunocitoquina para activar el receptor il-10ra humano y su uso.
Chen et al. Interlukin-18 is a pivot regulatory factor on matrix metalloproteinase-13 expression and brain astrocytic migration
Yang et al. Reconsideration of Classical Antibiotic Lincomycin: Anti-inflammatory Effect in LPS-stimulated RAW 264.7 Cells
MX2023007229A (es) Constructo de arn.
MX2023007228A (es) Constructo de arn.
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
Ding et al. Inhibiting SHP2 reduces glycolysis, promotes microglial M1 polarization, and alleviates secondary inflammation following spinal cord injury in a mouse model
AR115878A1 (es) Proteínas de fusión específicas para cd137 y pd-l1